Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: A brief overview

Expert Opinion on Drug Discovery

Volumn 6, Issue 8, 2011, Pages 855-869

  Parsa, Kishore V L ^a   Pal, Manojit ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Alogliptin; DPP IV inhibitor; Glucagon like peptide 1; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV; LINAGLIPTIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ARTICLE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MARKETING; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MEDICAL LITERATURE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 79960530809     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2011.588695     Document Type: Article

References (60)

1. Meetoo D, McGovern P, Safadi R. An epidemiological overview of diabetes across the world. Br J Nurs 2007;16:1002-7
2. Gupta R, Walunj SS, Tokala RK, et al. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of type 2 Diabetes. Curr Drug Targets 2009;10:71-87
3. Creutzfeldt W. The incretin concept today. Diabetologia 1979;16:75-85 (Pubitemid 9231263)
4. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30 (Pubitemid 34233752)
5. Irwin N, Flatt PR, Patterson S, et al. Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl- 3-N-tertbutylaminoquinoxaline. Eur J Pharmacol 2010;628:268-73
6. Nagakura T, Yasuda N, Yamazaki K, et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem Biophys Res Commun 2001;284:501-6 (Pubitemid 32918006)
7. Heins J, Welker P, Schonlein C, et al. Mechanism of proline-specific proteinases: (I) Substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from Flavobacterium meningosepticum. Biochim Biophys Acta 1988;954:161-9
8. Engel M, Hoffmann T, Wagner L, et al. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci USA 2003;100:5063-8 (Pubitemid 36542658)
9. Aertgeerts K, Ye S, Tennant MG, et al. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci 2004;13:412-21 (Pubitemid 38124962)
10. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24 (Pubitemid 29505281)
11. Blow DM, Birktoft JJ, Hartley BS. Role of a buried acid group in the mechanism of action of Chymotrypsin. Nature 1969;221:337-40
12. Wang XM, Yao TW, Nadvi NA, et al. Fibroblast activation protein and chronic liver disease. Front Biosci 2008;13:3168-80 (Pubitemid 351589228)
13. Keane Y, B-type natriuretic peptide FM, Nadvi NA, et al. Neuropeptide YY are novel substrates of fibroblast activation P and peptide substance protein-alpha. FEBS J 2011: published online 9 March 2011, doi: 10.1111/j.1742-4658.2011.08051.x
14. Ajami K, Pitman MR, Wilson CH, et al. Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett 2008;582:819-25
15. Geiss-Friedlander R, Parmentier N, Moller U, et al. The cytoplasmic peptidase DPP9 is rate-limiting for degradation of proline-containing peptides. J Biol Chem 2009;284:27211-19
16. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-94 (Pubitemid 41401097)
17. Havale SH, Pal M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem 2009;17:1783-802
18. Mulakayala N, Reddy UC, Iqbal J, et al. Synthesis of dipeptidyl peptidase-4 inhibitors: a brief overview. Tetrahedron 2010;66:4919-38
19. Kanstrup AB, Sams CK, Lundbeck JM, et al. DPP-IV-inhibiting purine derivatives for the treatment of diabetes. WO2003004496; 2003
20. Himmelsbach F, Mark M, Eckhardt M, et al. Xanthine derivative, production and use thereof as a medicament. WO2002068420; 2002
21. Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 2007;50:2297-300 (Pubitemid 46799241)
22. Zhang Z, Wallace MB, Feng J, et al. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV. J Med Chem 2011;54:510-24
23. Kodimuthali A, Prasunamba PL, Pal M. Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring. Beilstein J Org Chem 2010: published online 1 July 2010, doi: 10.3762/bjoc.6.71
24. Liu H, Ko SB, Josien H, et al. Selective N-functionalization of 6-substituted-2- pyridones. Tetrahedron Lett 1995;36:8917-20
25. Feng J, Gwaltney SL, Stafford JA, et al. Process for the preparation of pyrimidinedione derivatives. WO2007035629; 2007
26. Marom E, Mizhiritskii M, Rubnov S. Process for the preparation of alogliptin. WO 2010109468 A1; 2010
27. Deacon CF. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2008;9:402-13 (Pubitemid 351507666)
28. Burkey BF, Hoffmann PK, Hassiepen U, et al. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008;10:1057-61
29. Christopher R, Davenport M, Gwaltney S, et al. Pharmacokinetic and pharmacodynamic profiles of SYR-322, a novel inhibitor of dipeptidyl peptidase-IV, in rats, dogs, and monkeys. Diabetes 2006;55:Abs 452-P
30. Moritoh Y, Takeuchi K, Asakawa T, et al. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol 2008;588:325-32
31. Nagakura T, Yasuda N, Yamazaki K, et al. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism 2003;52:81-6
32. Moritoh Y, Takeuchi K, Asakawa T, et al. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. Br J Pharmacol 2009;157:415-26
33. Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab 2010;12:224-33
34. Moritoh Y, Takeuchi K, Hazama M. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther 2009;329:669-76
35. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[1,2,4]triazolo[4,3-a]pyrazin-7 (8H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141-51 (Pubitemid 40105255)
36. Mu J, Petrov A, Eiermann GJ, et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol 2009;623:148-54
37. Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006;55:1695-704 (Pubitemid 44324122)
38. Matveyenko AV, Dry S, Cox HI, et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009;58:1604-15
39. Kim SJ, Nian C, Doudet DJ, McIntosh CH. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice. Diabetes 2008;57:1331-9
40. Duttaroy A, Voelker F, Merriam K, et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur J Pharmacol 2011;650:703-7
41. Karim A, Bridson W, Fleck P, et al. Disposition of the dipeptidyl peptidase-4 inhibitor [14C]alogliptin benzoate ([14C]SYR-322) after oral administration to healthy male subjects. Abs Ann Meet Exposition Am Aassoc Pharm Scientists 2007
42. Moritoh Y, Takeuchi K, Asakawa T, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol 2009;602:448-54
43. DeFronzo RA, Fleck PR, Wilson CA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008;31:2315-17
44. Karim A, Fleck P, Hetman L, et al. Single dose pharmacokinetics of dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment [poster 538 P]. Diabetes 2008;57:A160
45. Karim A, Fleck P, Dorsey D, et al. Single dose pharmacokinetics of alogliptin benzoate (SYR-322) in subjects with moderate hepatic impairment [abstract 107]. J Clin Pharmacol 2007;47:1207
46. Launches of "NESINA-" for treatment of type 2 Diabetes, "UNISIA-" for treatment of hypertension and "Vectibix-", anti-cancer agent, in Japan. Takeda Pharmaceuticals Press release 2010
47. Takeda submits application in Japan for additional indications of alogliptin for combination therapy with sulfonylurea and combination therapy with biguanide. Takeda Pharmaceuticals Press release 2010
48. Takeda receives FDA complete response letter for alogliptin, an investigational treatment for type 2 Diabetes. Takeda Pharmaceuticals Press release 2009
49. Takeda initiates cardiovascular outcomes trial for alogliptin, an investigational treatment for type 2 Diabetes. Takeda Pharmaceuticals Press release 2009 (ClinicalTrials.gov Identifier: NCT00968708
50. Japan set for wave of new drug launches. Available from: http://www.pharmatimes. com/article/10-06-08/Japan-set-for-wave-of-new-drug- launches.aspx
51. Todd JF, Bloom SR. Incretins and other peptides in the treatment of diabetes. Diabet Med 2007;24:223-32
52. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132-8 (Pubitemid 46240373)
53. Karasik A, Aschner P, Katzeff H, et al. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008;24:489-96 (Pubitemid 351294398)
54. Stein PP, Williams-Herman D, Khatami H, et al. Sitagliptin, a selective DPP-4 inhibitor, is well tolerated in patients with type 2 diabetes: Pooled analysis of 5141 patients in clinical trials for up to 2 years. Diabetes 2007;56(Suppl 1):Abs 0534-P
55. Andukuri R, Drincic A, Rendell M. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes, Metab Syndr Obesity Targets Ther 2009;2:117-26
56. Patient information Januvia. Available from: www.fda.gov/medwatch/safety/ 2007/Oct-PI/Januvia-PI.pdf. [Last Accessed 22 October 2010]
57. He H, Tran P, Yin H, et al. Absorption, metabolism, and excretion of [14C] vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009;37:536-44
58. New Galvus clinical data reinforces efficacy profile; safety update provided to regulatory agencies. Novartis AG Press release 2007
59. FDA prescribing information Information for Healthcare Professionals - Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). Available from: http://www. fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsand Providers/DrugSafetyInformationfor HeathcareProfessionals/ucm183764.htm [Last accessed on 22 October 2010]
60. Triplitt C, Cersosimo E, DeFronzo RA. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc Health Risk Manag 2010;6:671-90